With potentially $100 billion in annual sales by 2030 up for grabs, the competition in the GLP-1 weight loss drugs space is predictably heating up, with Eli Lilly and Company (LLY) going head-to-head with the European pharma giant Novo Nordisk (NVO). A new study has upended the perceived parity between these two pharma heavy-weights, however, with Eli Lilly and Company managing to score a direct hit against Novo Nordisk. JAMA Study: Use Of Eli Lilly And Company's GLP-1 Agonist Tirzepatide Was Associated With Significantly Greater Weight Loss Than Novo Nordisk's Semaglutide For the benefit of those who might not be […]
Read full article at https://wccftech.com/eli-lilly-and-company-glp-1-weight-loss-drug-is-much-more-effective-than-novo-nordisk/
WccftechContinue reading/original-link]